Manhattan Scientifics announced that Loraine Upham has been engaged as a consultant to support its cancer team.
According to a release, the technology, developed by Edward R. Flynn, PhD, provides the most specific and most sensitive method for detecting cancer currently known. Upham's role will be to identify initial markets and facilitate relationships with strategic partners for the company.
Loraine Upham has over 30 years of biotechnology commercialization experience. She is best known for her co- invention and development of a novel treatment for diabetes that was partnered in a $335M deal with Sanofi-Aventis in 2010.
Upham said, "It is an honor to work with Dr. Flynn and the Senior Scientific team led by its president Gerald Grafe. This company has terrific potential to impact markets in a number of sectors through strategic partnerships. The technology is extraordinary and can be applied to everything from drug discovery and development and in vitro diagnostics to in vivo animal imaging and quantification, while human clinical applications are established."
Senior Scientific, a unit of Manhattan Scientifics, is pioneering the technology, driving it from "bench to bedside," the Company noted. The technology uses non-toxic iron oxide nanoparticles and ultrasensitive magnetic detection for a highly sensitive and very specific approach to cancer detection that can locate and measure tumors one millionth the size detectable by X-Rays and MRI.
Marvin Maslow, Manhattan Scientifics' founder said, "We are involved in early collaborative planning with the U.S.'s No. 1 cancer research hospital because of our company's ability to find cancers years before other known methods."
Manhattan Scientifics is focused on technology transfer and commercialization of transformative technologies in the nano medicine space.
((Comments on this story may be sent to email@example.com))